Latest posts
-
One Extreme Example, One Big Question: Should India Put Every Medicine Under Price Control?
The Supreme Court’s intervention on drug pricing raises a legitimate concern. But it also opens a much larger question: how should India balance the affordability of medicines today with the investment needed to…
-
How Can a Pharmaceutical Company Prove That Its Strategic Decisions Made Healthcare Better—Measurably?
From strategic intent to measurable patient impact: a practical roadmap for Indian pharma Pharmaceutical companies routinely describe their strategies as patient-centric, evidence-based and outcome-oriented. But there…
-
Indian Pharma Has a Leadership Challenge: Can Patient Value, Employee Fulfilment and Business Growth Become the Same Goal?
India’s pharmaceutical industry is entering another important phase of growth. The ambition is clear. The industry is being encouraged to invest more in clinical research and R&D, move towards higher-value products,…
-
Who Is Really Protecting the Medicine After It Leaves the Factory?
The Abhayrab episode exposes a vulnerability that Indian pharma can no longer treat merely as a counterfeit-drug problem On September 5, 2026, India’s Central Drugs Standard Control Organization (CDSCO) issued a public…
-
Why Geopolitics Is Becoming a Major Business Risk for Indian Pharma
How tariffs, trade tensions and disrupted supply routes could reshape the industry’s future In August 2026, an important warning emerged for India’s pharmaceutical industry. According to a Reuters report, India’s pharma…
-
Evidence-Based Brand Value: The GLP-1 Test for the Future of Indian Pharma Marketing
Can brand preference increasingly be earned by demonstrating value rather than merely promoting it? Several themes explored in my earlier articles now appear to converge on one important question for Indian pharma. The…
-
When Systems Create Blind Spots: The Hidden Risk in Indian Pharma’s Growing Complexity
India’s pharmaceutical industry is becoming more sophisticated, interconnected and complex than ever before. A single medicine may now involve API suppliers, formulation developers, technology partners, contract…
-
Beyond New Molecules: Why India Must Broaden Its Understanding of Pharmaceutical Innovation
For more than two decades, the conversation on pharmaceutical patents in India has revolved around a familiar set of themes — product patents, Section 3(d) of the Patents Act, evergreening, compulsory licensing, and the…
-
From Regulatory Reform to Global Competitiveness – Where Does Indian Pharma Go from Here?
Executive Summary: On July 30, 2026, Reuters reported that India’s pharmaceutical quality initiative—launched in response to quality concerns that emerged in late 2022—had resulted in regulatory action against…
-
The Age of Accountability: What India’s Pharmaceutical Industry Must Learn from a Public Movement
Recent policy initiatives suggest the Government is responding to changing public expectations. Should the pharmaceutical industry do the same—for the sake of patients? Executive Summary: India is witnessing a profound…